ACTRN12610000518066
Not yet recruiting
未知
aser vapourization of the prostate in men with benign prostate enlargement. Long term results and cost analysis.
Philip McCahy0 sites150 target enrollmentJune 23, 2010
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Benign prostate enlargement
- Sponsor
- Philip McCahy
- Enrollment
- 150
- Status
- Not yet recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Urinary flow rate \< 15mls/sec, IPSS \> 12
Exclusion Criteria
- •Prostate cancer, inability to provide informed consent
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
aser enucleation of the prostate for benign prostatic hyperplasiaN40Hyperplasia of prostateDRKS00008206Asklepios Klinik Barmbek110
Completed
Not Applicable
sing a high-power thulium laser system in the operation to treat benign prostate hyperplasiarinary frequency, nocturia, weak stream, or urine retentionUrological and Genital DiseasesISRCTN52339705Taipei Veterans General Hospital35
Recruiting
Not Applicable
Embolisation of the prostatic artery in patients with symptomatic benign prostate hyperplasia: A prospective single arm cohort-study.benign prostate hypertrofiabenign prostate tumour10038593NL-OMON52683Sint Elisabeth Ziekenhuis25
Active, not recruiting
Not Applicable
A Clinical Phase II Study in Patients with Prostate Cancer and Bone Metastases with KML001 (KOMINOX®) - KML001 in patients with prostate cancer and bone metastasesProstate Cancer MetastaticMedDRA version: 8.1Level: LLTClassification code 10036909Term: Prostate cancer metastaticEUCTR2006-005607-33-DEKOMINOX USA, Inc.
Not yet recruiting
Not Applicable
In patients with benign prostate hyperplasia who received tamsulosin 0.2 mg for more than 4 weeks, the improvement of the lower urinary tract symptom terazosin 5 mg administered for 12 weeksKCT0004566Dankook Univeristy Hospital51